Compounds > dapsone
Page last updated: 2024-10-25

dapsone and Acne

dapsone has been researched along with Acne in 70 studies

Research Excerpts

ExcerptRelevanceReference
"Dapsone gel, 5% is administered twice daily for the treatment of acne vulgaris, and some patients may find adherence challenging."9.22Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: Second of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-Controlled Trials. ( Berk, DR; Chang-Lin, JE; Eichenfield, LF; Frankel, EH; Jones, TM; Kaoukhov, A; Lain, T; Ruan, S, 2016)
"To analyze the current literature studying the efficacy of topical dapsone in the treatment of acne."9.22Topical dapsone in the treatment of acne: a systematic review. ( Lake, E; Nickles, MA, 2022)
" Meta-analysis showed that dapsone gel alone or dapsone gel combined with isotretinoin was superior to excipient alone or oral isotretinoin alone in the treatment of acne (OR =1."9.22Efficacy and safety of dapsone gel for acne: a systematic review and meta-analysis. ( Liu, H; Sun, L; Wang, X; Wang, Z; Zhang, F, 2022)
"To assess the safety and efficacy of combination therapy with dapsone 5% gel with oral doxycycline hyclate 100mg, followed by monotherapy with dapsone 5% gel in improving and maintaining response in patients with moderate to severe acne."9.22Use of Dapsone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Dapsone 5% Gel Combination Treatment. ( Kircik, LH, 2016)
"Topical dapsone gel, 5% is approved for treatment of acne vulgaris but has not been studied specifically in women with skin of color (SOC; Fitzpatrick skin types IV, V, or VI)."9.22The Efficacy and Safety of Topical Dapsone Gel, 5% for the Treatment of Acne Vulgaris in Adult Females With Skin of Color. ( Alexis, AF; Burgess, C; Callender, VD; Gallagher, CJ; Herzog, JL; Roberts, WE; Schweiger, ES; Stockton, TC, 2016)
"Treatment of acne vulgaris (acne) with dapsone gel, 5% requires twice-daily dosing, and some patients may not adhere to this regimen."9.22Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled Trials. ( Berk, DR; Berlin, JM; Bucko, AD; Bukhalo, M; Chang-Lin, JE; Grekin, SK; Jarratt, MT; Kaoukhov, A; Lin, V; Stein Gold, LF; Weiss, JS, 2016)
"The response to dapsone 5% gel appears to be influenced by gender, with female patients experiencing a significantly greater reduction in acne lesion counts and a significantly higher clinical success rate following 12 weeks of treatment."9.16The efficacy and tolerability of dapsone 5% gel in female vs male patients with facial acne vulgaris: gender as a clinically relevant outcome variable. ( Harper, JC; Oefelein, MG; Tanghetti, E, 2012)
"To evaluate the safety and efficacy of dapsone gel 5% in the treatment of acne when used in combination with adapalene gel 0."9.14Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12-week, randomized, double-blind study. ( Abramovits, W; Eichenfield, LF; Fleischer, AB; Garrett, S; Lucky, A; Shalita, A, 2010)
" long-term, open-label, noncomparative safety study were conducted to evaluate the efficacy and safety of dapsone gel 5% in patients with acne vulgaris."9.13Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents. ( Bourcier, M; Garrett, S; Maloney, JM; Papp, K; Raimer, S; Siegfried, E; Wilson, D, 2008)
"To evaluate the risk of hemolysis in subjects with glucose-6-phosphate dehydrogenase (G6PD) deficiency who were treated for acne vulgaris with either dapsone gel, 5% (dapsone gel), or vehicle gel."9.13Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris. ( Jarratt, M; Pariser, D; Piette, WW; Sheth, P; Taylor, S; Wilson, D, 2008)
"Dapsone gel 5%, a topical formulation of dapsone, was shown to deliver clinically effective doses of dapsone with minimal systemic absorption in 2 randomized, vehicle-controlled, 12-week studies of patients with acne vulgaris."9.12Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment. ( Garrett, S; Jones, T; Ling, M; Lucky, AW; Maloney, JM; Roberts, J; Taylor, S, 2007)
"The goal of these studies was to evaluate the efficacy and safety of dapsone gel, 5% in the treatment of acne."9.12Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. ( Carter, E; Draelos, ZD; Elewski, B; Garrett, S; Lynde, C; Maloney, JM; Poulin, Y, 2007)
"Sixty years ago, Ross discussed the use of oral dapsone in the treatment of acne vulgaris."9.12Dapsone for acne: Still in use after half a century! ( Al-Niaimi, F; Ali, FR; Searle, T, 2021)
"Oral dapsone has been available for over 60 years and has been used to treat severe acne vulgaris; however, the oral formulation is known to cause dose-dependent haematological reactions and is currently indicated only for diseases such as dermatitis herpetiformis and Hansen's disease."9.12Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris. ( Garrett, S; Halder, R; Sharata, H; Thiboutot, DM; Willmer, J, 2007)
"We describe a patient with PASH syndrome and report about the successful multimodal treatment with infliximab, cyclosporine, and dapsone."8.91Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone. ( Braun-Falco, M; Goerdt, S; Leverkus, M; Lohse, P; Pfannschmidt, N; Staub, J; Strohal, R, 2015)
"The aims of this study were to review the published literature on dapsone pharmacology and pharmacokinetics, and to evaluate the gel's efficacy and safety in treating acne vulgaris, and finally to provide personal insight into its future as a topical agent for acne vulgaris."8.85An evaluation of dapsone gel 5% in the treatment of acne vulgaris. ( Pickert, A; Raimer, S, 2009)
"Allergen Inc has launched Aczone, a topical gel formulation of the antibacterial, anti-inflammatory agent dapsone, for the potential treatment of acne vulgaris."8.85Aczone, a topical gel formulation of the antibacterial, anti-inflammatory dapsone for the treatment of acne. ( Scheinfeld, N, 2009)
"A 19-year-old man with nodulocystic acne on baseline was treated with isotretinoin therapy."8.84Pyoderma gangrenosum following isotretinoin therapy for acne nodulocystic. ( Avelleira, JC; Azulay, D; Maciel, G; Soares, D; Tamler, C; Tinoco, MP, 2008)
" Dapsone (DAP) is an antibacterial used as anti-acne agent, but challenged by low water solubility and poor skin permeability."8.31Dapsone-Loaded Mixed Micellar Gel for Treatment OF Acne Vulgaris. ( Deshpande, P; Deshpande, S; Rao, MR, 2023)
"Dapsone gel is a topical treatment for facial acne in adolescents and adults, and while systemic dapsone therapy is known to be associated with methemoglobinemia, once-daily topical dapsone has been well tolerated with few side effects in large randomized controlled trials."7.96Severe methemoglobinemia due to topical dapsone misuse in a teenage girl. ( McCarthy, J; McCarthy, P; McFadden, V; Stefanko, N; Yale, S, 2020)
"Male and female adults and adolescents with facial acne, representing a broad range of ages, skin phototypes, and ethnicities, and with no prior use of dapsone gel, 7."7.88Clinical Experience With Once-Daily Dapsone Gel, 7.5% Monotherapy in Patients With Acne Vulgaris. ( Alvandi, N; Lain, E; Stockton, TC; Tanghetti, EA; Zeichner, JA, 2018)
"Dapsone 5% gel for the topical treatment for acne vulgaris was recently introduced in Canada."7.78Dapsone 5% gel: a new option in topical therapy for acne. ( Tan, J, 2012)
" Efficacy was evaluated using the Global Acne Assessment Score (GAAS), lesion counts, and Acne Symptom and Impact Scale (ASIS); adverse events (AEs) and tolerability were also assessed."6.87Efficacy, Safety, and Tolerability of Topical Dapsone Gel, 7.5% for Treatment of Acne Vulgaris by Fitzpatrick Skin Phototype. ( Alexis, AF; Alvandi, N; Callender, VD; Cook-Bolden, FE; Downie, JB; McMichael, A; Rodriguez, DA; Taylor, SC, 2018)
"Introduction: Acne vulgaris is more common in females than males and is challenging to treat."6.87Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females ( Alvandi, N; Bai, Z; Baldwin, H; Harper, J; Kircik, L; Tanghetti, E, 2018)
"Introduction: Acne vulgaris is more common in females than males and is challenging to treat."6.87Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females ( Alvandi, N; Bai, Z; Baldwin, H; Harper, J; Kircik, L; Tanghetti, E, 2018)
"Introduction: Acne vulgaris is more common in females than males and is challenging to treat."6.87Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females ( Alvandi, N; Bai, Z; Baldwin, H; Harper, J; Kircik, L; Tanghetti, E, 2018)
"

BACKGROUND: Acne vulgaris has varying physical and psychological effects in men and women of different ages, races, and ethnicities."

6.84Treatment Response With Once-Daily Topical Dapsone Gel, 7.5% for Acne Vulgaris: Subgroup Analysis of Pooled Data from Two Randomized, Double-Blind Stu. ( Berk, DR; Bruce, S; Chang-Lin, JE; Downie, J; Draelos, ZD; Kaoukhov, A; Kempers, SE; Peredo, MI; Rodriguez, DA; Ruan, S, 2017)
"Dapsone treatment can cause a variety of side effects that can be categorized as pharmacological, dose-related, allergic, or idiosyncratic reactions."6.82Dapsone for the treatment of acne vulgaris: do the risks outweigh the benefits? ( Daye, M; Temiz, SA, 2022)
" Safety profile assessments included adverse events (AEs), physical examinations, laboratory tests, and local tolerability assessments."6.82Safety and Pharmacokinetics of Once-Daily Dapsone Gel, 7.5% in Patients With Moderate Acne Vulgaris. ( Berk, DR; Chang-Lin, JE; Jarratt, MT; Jones, TM; Kaoukhov, A; Lin, V; Tong, W, 2016)
"To assess the safety and efficacy of dapsone gel 5%, an anti-inflammatory agent, in combination with tazarotene cream 0."6.76Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris. ( Dhawan, S; Downie, J; Draelos, Z; Germain, MA; Green, L; Kasteler, JS; Kircik, L; Ling, M; Oefelein, MG; Tanghetti, E, 2011)
" For many years scientists explored the possibility of developing a topical formulation of dapsone for the treatment of acne in the hope of minimizing the adverse hematologic effects of oral dapsone."6.45Dapsone 5% gel: a review of its efficacy and safety in the treatment of acne vulgaris. ( Kissling, RF; Shalita, AR; Stotland, M, 2009)
"A 19-year-old Japanese man had been treated for ulcerative colitis for 2 years."5.37A case of acne fulminans in a patient with ulcerative colitis successfully treated with prednisolone and diaminodiphenylsulfone: a literature review of acne fulminans, rosacea fulminans and neutrophilic dermatoses occurring in the setting of inflammatory ( Danno, K; Fujimoto, N; Tanaka, T; Uenishi, T; Wakabayashi, M, 2011)
"We report its successful use in acne inversa."5.31[Acne inversa: a dapsone-sensitive dermatosis]. ( Hofer, T; Itin, PH, 2001)
"Isotretinoin has revolutionized the treatment of severe acne unresponsive to oral antibiotics."5.30Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone. ( Lear, JT; Smith, AG; Tan, BB, 1997)
"To analyze the current literature studying the efficacy of topical dapsone in the treatment of acne."5.22Topical dapsone in the treatment of acne: a systematic review. ( Lake, E; Nickles, MA, 2022)
"Topical dapsone gel, 5% is approved for treatment of acne vulgaris but has not been studied specifically in women with skin of color (SOC; Fitzpatrick skin types IV, V, or VI)."5.22The Efficacy and Safety of Topical Dapsone Gel, 5% for the Treatment of Acne Vulgaris in Adult Females With Skin of Color. ( Alexis, AF; Burgess, C; Callender, VD; Gallagher, CJ; Herzog, JL; Roberts, WE; Schweiger, ES; Stockton, TC, 2016)
"Dapsone gel, 5% is administered twice daily for the treatment of acne vulgaris, and some patients may find adherence challenging."5.22Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: Second of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-Controlled Trials. ( Berk, DR; Chang-Lin, JE; Eichenfield, LF; Frankel, EH; Jones, TM; Kaoukhov, A; Lain, T; Ruan, S, 2016)
" Meta-analysis showed that dapsone gel alone or dapsone gel combined with isotretinoin was superior to excipient alone or oral isotretinoin alone in the treatment of acne (OR =1."5.22Efficacy and safety of dapsone gel for acne: a systematic review and meta-analysis. ( Liu, H; Sun, L; Wang, X; Wang, Z; Zhang, F, 2022)
"Benzoyl peroxide (BPO) is a cornerstone of acne therapy, often used in combination with a topical antibiotic and/or a retinoid."5.17Tolerability and irritation potential of four topical acne regimens in healthy subjects. ( Grove, G; Gwazdauskas, J; Zerweck, C, 2013)
"To evaluate the risk of hemolysis in subjects with glucose-6-phosphate dehydrogenase (G6PD) deficiency who were treated for acne vulgaris with either dapsone gel, 5% (dapsone gel), or vehicle gel."5.13Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris. ( Jarratt, M; Pariser, D; Piette, WW; Sheth, P; Taylor, S; Wilson, D, 2008)
"Sixty years ago, Ross discussed the use of oral dapsone in the treatment of acne vulgaris."5.12Dapsone for acne: Still in use after half a century! ( Al-Niaimi, F; Ali, FR; Searle, T, 2021)
"We describe a patient with PASH syndrome and report about the successful multimodal treatment with infliximab, cyclosporine, and dapsone."4.91Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone. ( Braun-Falco, M; Goerdt, S; Leverkus, M; Lohse, P; Pfannschmidt, N; Staub, J; Strohal, R, 2015)
"  The solvent diethylene glycol monoethyl ether (DEGEE) is currently used in over 500 cosmetic products and has enabled the formulation of a topical 5% dapsone gel for the treatment of acne."4.87Diethylene glycol monoethyl ether: an emerging solvent in topical dermatology products. ( Osborne, DW, 2011)
"Allergen Inc has launched Aczone, a topical gel formulation of the antibacterial, anti-inflammatory agent dapsone, for the potential treatment of acne vulgaris."4.85Aczone, a topical gel formulation of the antibacterial, anti-inflammatory dapsone for the treatment of acne. ( Scheinfeld, N, 2009)
"A 19-year-old man with nodulocystic acne on baseline was treated with isotretinoin therapy."4.84Pyoderma gangrenosum following isotretinoin therapy for acne nodulocystic. ( Avelleira, JC; Azulay, D; Maciel, G; Soares, D; Tamler, C; Tinoco, MP, 2008)
"Newer topical therapies approved by the US Food and Drug Administration (FDA) for the treatment of acne vulgaris are dapsone gel 5% and clindamycin phosphate 1."4.84Newer topical therapies for the treatment of acne vulgaris. ( Del Rosso, JQ, 2007)
" The following drugs are undoubtedly effective and sometimes even the therapy of choice: tetracyclines in acne vulgaris and rosacea (including rosacea keratitis); penicillin G in acrodermatitis atrophicans and cold urticaria; dapsone in dermatitis herpetiformis and - as a powerful adjuvant - in acne vulgaris and rosacea."4.76[Positive side-effects of antibiotic and antimicrobial drugs in therapy (author's transl)]. ( Illig, L, 1979)
"This study aimed to illustrate the use of D-optimal mixture design (DOMD) for optimization of an enhancer containing Dapsone niosomal formula for acne topical treatment."4.12D-optimal mixture design for optimization of topical dapsone niosomes: in vitro characterization and in vivo activity against ( Abdeltawab, NF; Habib, BA; Salah Ad-Din, I, 2022)
"Dapsone gel is a topical treatment for facial acne in adolescents and adults, and while systemic dapsone therapy is known to be associated with methemoglobinemia, once-daily topical dapsone has been well tolerated with few side effects in large randomized controlled trials."3.96Severe methemoglobinemia due to topical dapsone misuse in a teenage girl. ( McCarthy, J; McCarthy, P; McFadden, V; Stefanko, N; Yale, S, 2020)
"Dapsone 5% gel for the topical treatment for acne vulgaris was recently introduced in Canada."3.78Dapsone 5% gel: a new option in topical therapy for acne. ( Tan, J, 2012)
"Topical dapsone gel 5% is indicated for the treatment of acne vulgaris and has been marketed since late 2008."3.76Is topical dapsone safe in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients? ( Webster, GF, 2010)
" To investigate these interaction phenomena, topical dapsone gel and sulfacetamide sodium lotion were combined with various topical acne treatments, including benzoyl peroxides, clindamycin phosphate, and retinoids."3.75Interaction of topical sulfacetamide and topical dapsone with benzoyl peroxide. ( Dubina, MI; Fleischer, AB, 2009)
" Efficacy was evaluated using the Global Acne Assessment Score (GAAS), lesion counts, and Acne Symptom and Impact Scale (ASIS); adverse events (AEs) and tolerability were also assessed."2.87Efficacy, Safety, and Tolerability of Topical Dapsone Gel, 7.5% for Treatment of Acne Vulgaris by Fitzpatrick Skin Phototype. ( Alexis, AF; Alvandi, N; Callender, VD; Cook-Bolden, FE; Downie, JB; McMichael, A; Rodriguez, DA; Taylor, SC, 2018)
"

BACKGROUND: Acne vulgaris has varying physical and psychological effects in men and women of different ages, races, and ethnicities."

2.84Treatment Response With Once-Daily Topical Dapsone Gel, 7.5% for Acne Vulgaris: Subgroup Analysis of Pooled Data from Two Randomized, Double-Blind Stu. ( Berk, DR; Bruce, S; Chang-Lin, JE; Downie, J; Draelos, ZD; Kaoukhov, A; Kempers, SE; Peredo, MI; Rodriguez, DA; Ruan, S, 2017)
" Safety profile assessments included adverse events (AEs), physical examinations, laboratory tests, and local tolerability assessments."2.82Safety and Pharmacokinetics of Once-Daily Dapsone Gel, 7.5% in Patients With Moderate Acne Vulgaris. ( Berk, DR; Chang-Lin, JE; Jarratt, MT; Jones, TM; Kaoukhov, A; Lin, V; Tong, W, 2016)
"Dapsone has antimicrobial effects stemming from its sulfonamide-like ability to inhibit the synthesis of dihydrofolic acid."2.66Update on the use of dapsone in dermatology. ( Abbas, O; Ghaoui, N; Hanna, E; Kibbi, AG; Kurban, M, 2020)
"Recognition that acne is an inflammatory condition, not an infectious one, has led to a call for reduction in antibiotic use."2.61An Overview of Acne Therapy, Part 1: Topical therapy, Oral Antibiotics, Laser and Light Therapy, and Dietary Interventions. ( Baldwin, HE; Marson, JW, 2019)
"Acne vulgaris (acne) is the most common skin disease we see in dermatology practice."2.58Management of comedonal acne vulgaris with fixed-combination topical therapy. ( Baldwin, H; Gold, MH; Lin, T, 2018)
"Acne and rosacea are common conditions seen every day by dermatologists."2.53What's new in acne and rosacea? ( Keri, J, 2016)
"Effective medications to treat acne sometimes become unavailable in certain countries, either for economic reasons or for shortage of them in the pharmaceutical market."2.42Less common methods to treat acne. ( Kaminsky, A, 2003)
"Acne vulgaris is a pervasive inflammatory disorder of the skin, with multiple etiologies and treatment options."1.40Acne vulgaris in the context of complex medical co-morbities: the management of severe acne vulgaris in a female with retinitis pigmentosa - utilizing pulse dye laser in conjunction with medical therapy. ( Keck, L; Shariff, A; Zlotoff, B, 2014)
"A 19-year-old Japanese man had been treated for ulcerative colitis for 2 years."1.37A case of acne fulminans in a patient with ulcerative colitis successfully treated with prednisolone and diaminodiphenylsulfone: a literature review of acne fulminans, rosacea fulminans and neutrophilic dermatoses occurring in the setting of inflammatory ( Danno, K; Fujimoto, N; Tanaka, T; Uenishi, T; Wakabayashi, M, 2011)
"We report its successful use in acne inversa."1.31[Acne inversa: a dapsone-sensitive dermatosis]. ( Hofer, T; Itin, PH, 2001)
"Isotretinoin has revolutionized the treatment of severe acne unresponsive to oral antibiotics."1.30Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone. ( Lear, JT; Smith, AG; Tan, BB, 1997)

Research

Studies (70)

TimeframeStudies, this research(%)All Research%
pre-199012 (17.14)18.7374
1990's2 (2.86)18.2507
2000's14 (20.00)29.6817
2010's31 (44.29)24.3611
2020's11 (15.71)2.80

Authors

AuthorsStudies
Temiz, SA1
Daye, M1
Nickles, MA1
Lake, E1
Wang, X1
Wang, Z1
Sun, L1
Liu, H1
Zhang, F1
Habib, BA1
Abdeltawab, NF1
Salah Ad-Din, I1
Rao, MR1
Deshpande, S1
Deshpande, P1
Legal, K1
Misery, L1
Yale, S1
Stefanko, N1
McCarthy, P1
McFadden, V1
McCarthy, J1
Ghaoui, N1
Hanna, E1
Abbas, O1
Kibbi, AG1
Kurban, M1
Furukawa, F1
Makino, T1
Mori, S1
Shimizu, T1
Searle, T1
Al-Niaimi, F1
Ali, FR1
Draelos, ZD2
Rodriguez, DA2
Kempers, SE1
Bruce, S1
Peredo, MI1
Downie, J2
Chang-Lin, JE4
Berk, DR4
Ruan, S2
Kaoukhov, A4
Gold, MH1
Baldwin, H4
Lin, T1
Taylor, SC1
Cook-Bolden, FE1
McMichael, A1
Downie, JB1
Alexis, AF2
Callender, VD2
Alvandi, N6
Stockton, TC2
Tanghetti, EA1
Lain, E1
Zeichner, JA1
Sardana, K1
Bajaj, S1
Bose, SK1
Tanghetti, E5
Harper, J3
Kircik, L4
Bai, Z3
Geyfman, M1
Debabov, D1
Poloso, N1
Marson, JW1
Baldwin, HE1
El-Nabarawi, MA1
Shamma, RN1
Farouk, F1
Nasralla, SM1
Wakabayashi, M3
Fujii, N2
Fujimoto, N3
Tanaka, T3
Grove, G1
Zerweck, C1
Gwazdauskas, J1
Shariff, A1
Keck, L1
Zlotoff, B1
Staub, J1
Pfannschmidt, N1
Strohal, R1
Braun-Falco, M1
Lohse, P1
Goerdt, S1
Leverkus, M1
Kircik, LH2
Burgess, C1
Herzog, JL1
Roberts, WE1
Schweiger, ES1
Gallagher, CJ1
Stein Gold, LF1
Jarratt, MT2
Bucko, AD1
Grekin, SK1
Berlin, JM1
Bukhalo, M1
Weiss, JS1
Lin, V2
Keri, J1
Eichenfield, LF2
Lain, T1
Frankel, EH1
Jones, TM2
Didona, D1
Paolino, G1
Donati, P1
Muscardin, LM1
Tong, W1
Al-Salama, ZT1
Deeks, ED1
Tinoco, MP1
Tamler, C1
Maciel, G1
Soares, D1
Avelleira, JC1
Azulay, D1
Piette, WW1
Taylor, S2
Pariser, D1
Jarratt, M1
Sheth, P1
Wilson, D2
Scheinfeld, N1
Stotland, M1
Shalita, AR1
Kissling, RF1
Pickert, A1
Raimer, S2
Dubina, MI1
Fleischer, AB2
Shalita, A1
Abramovits, W1
Lucky, A1
Garrett, S5
Webster, GF1
Uenishi, T1
Danno, K1
Dhawan, S1
Green, L1
Ling, M2
Germain, MA1
Kasteler, JS1
Oefelein, MG2
Draelos, Z1
Osborne, DW1
Tan, J1
Harper, JC1
Kaminsky, A1
ROSS, CM1
Degitz, K1
Plewig, G1
Carter, E1
Maloney, JM3
Elewski, B1
Poulin, Y1
Lynde, C1
Thiboutot, DM1
Willmer, J1
Sharata, H1
Halder, R1
Lucky, AW1
Roberts, J1
Jones, T1
Del Rosso, JQ1
Bourcier, M1
Papp, K1
Siegfried, E1
Barranco, VP1
Geniaux, M1
Meraud, JP1
Texier, L1
Blanken, R1
van Voorst Vader, PC1
Endre, ZH1
Charlesworth, JA1
Macdonald, GJ1
Woodbridge, L1
Reeves, JR1
Tomecki, KJ1
Catalano, CJ1
Tan, BB1
Lear, JT1
Smith, AG1
Corp, CC1
Ghishan, FK1
Hofer, T1
Itin, PH1
Illig, L1
Koller, WC1
Gehlmann, LK1
Malkinson, FD1
Davis, FA1
Ismail, R1
Baliavichene, GR1
Prendiville, JS1
Logan, RA1
Russell-Jones, R1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Safety and Efficacy Study to Compare Dapsone Dermal Gel With Vehicle Control in Patients With Acne Vulgaris[NCT01974141]Phase 32,102 participants (Actual)Interventional2013-11-30Completed
A Safety and Efficacy Study to Compare Dapsone Dermal Gel With Vehicle Control in Patients With Acne Vulgaris[NCT01974323]Phase 32,238 participants (Actual)Interventional2013-11-30Completed
[NCT01773122]Phase 177 participants (Actual)Interventional2013-01-21Completed
ACZ ACN 01. A Phase 4, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Cross-Over Study to Further Evaluate the Risk of Hematological Adverse Events in G6PD-Deficient Subjects With Acne Vulgaris Treated With ACZONE™ (Dapsone) Gel, 5%.[NCT00243542]Phase 464 participants (Actual)Interventional2005-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

"Percentage of Patients Reporting Very Good or Excellent on Item 10 of the 5-Point Acne Symptom Impact Scale (ASIS)"

"The patient assessed the impact of their acne vulgaris on the look of their face using item 10 on the 5-point ASIS. Item 10 scores range from 1 (Excellent) to 5 (Bad). The percentage of patients who had an ASIS score of 4 (Fair) or 5 (Bad) at baseline and who reported Very good or Excellent at Week 12 are reported." (NCT01974141)
Timeframe: Week 12

InterventionPercentage of Patients (Number)
Dapsone Gel23.8
Dapsone Gel Vehicle19.2

Percentage Change From Baseline in Total Lesion Counts

The Investigator evaluated the patient's Inflammatory (papule, pustule and nodule/cyst) and Non-inflammatory (blackhead and whitehead) lesions. A papule is a small, red, solid elevation less than 1.0 cm in diameter, a pustule is a small, circumscribed elevation of the skin that contains yellow-white exudate and a nodule/cyst is a circumscribed, elevated, solid lesion generally more than 0.5 cm in diameter with palpable depth. The total lesion count was the sum of the inflammatory and non-inflammatory lesion counts. A negative percent change from baseline indicates a reduction in lesion counts (improvement) and a positive percent change from baseline indicates an increase in lesion counts (worsening). (NCT01974141)
Timeframe: Baseline, Week 12

InterventionPercent Change in Lesion Count (Least Squares Mean)
Dapsone Gel-48.7
Dapsone Gel Vehicle-42.4

Percentage of Patients Reporting at Least a 1-Grade Improvement From Baseline in Facial Oiliness on a the 5-Point ASIS Scale

The patient assessed their facial oiliness using item 1 on the 5-point ASIS. Item 1 scores ranged from 0 (Not at all oily) to 4 (Very oily). The percentage of patients who reported at least a 1-grade improvement from baseline in their facial oiliness are reported. (NCT01974141)
Timeframe: Baseline, Week 12

InterventionPercentage of Patients (Number)
Dapsone Gel45.7
Dapsone Gel Vehicle51.8

Percentage of Patients Reporting at Least a 1-Grade Improvement From Baseline in Facial Redness on a the 5-Point ASIS Scale

The patient assessed their facial redness using item 8 on the 5-point ASIS. Item 8 scores ranged from 0 (Not at all red) to 4 (Very red). The percentage of patients who reported at least a 1-grade improvement from baseline in their facial redness are reported. (NCT01974141)
Timeframe: Baseline, Week 12

InterventionPercentage of Patients (Number)
Dapsone Gel55.6
Dapsone Gel Vehicle53.0

Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS)

The Investigator evaluated the patient's acne severity using the 5-point GAAS scale with 0 being none and 4 being severe. The complete scale is as follow: Grade 0 (none) = No evidence of facila acne vulgaris; Grade 1 (minimal) = Few noninflammatory lesions (comedones) are present, a few inflammatory lesions (papules/pustules) may be present, no nodulo-cyctic lesions are allowed; Grade 2 (mild) = Several to many noninflammatory lesions (comedones) are present, a few inflammatory lesions (papules/pustules) are present, no nodulo-cystic lesions are allowed; Grade 3 (moderate) = Many noninflammatory (comedones) and inflammatory lesions (papules/pustules) are present, no nodulo-cystic lesions are allowed; Grade 4 (severe) = Significant degree of inflammatory disease, papules/pustules are a predominant feature, a few nodulo-cystic lesions may be present, comedones may be present. (NCT01974141)
Timeframe: Week 12

InterventionPercentage of Patients (Number)
Dapsone Gel29.9
Dapsone Gel Vehicle21.2

Change From Baseline in Inflammatory Facial Lesion Counts

The Investigator evaluated the patient's inflammatory lesions (papule, pustule and nodule/cyst). A negative change from baseline indicates a reduction in lesion counts (improvement) and a positive change from baseline indicates an increase in lesion counts (worsening). (NCT01974141)
Timeframe: Baseline, Week 12

,
InterventionNumber of Inflammatory Lesions (Mean)
BaselineChange from Baseline at Week 12
Dapsone Gel29.0-16.1
Dapsone Gel Vehicle29.4-14.1

Change From Baseline in Noninflammatory Facial Lesion Counts

The Investigator evaluated the patient's noninflammatory lesions (papule, pustule and nodule/cyst). A negative change from baseline indicates a reduction in lesion counts (improvement) and a positive change from baseline indicates an increase in lesion counts (worsening). (NCT01974141)
Timeframe: Baseline, Week 12

,
InterventionNumber of Noninflammatory Lesions (Mean)
BaselineChange from Baseline at Week 12
Dapsone Gel47.0-20.8
Dapsone Gel Vehicle48.7-17.6

Change From Baseline in the 9-Item ASIS Sign Domain Score

The patient assessed signs of acne vulgaris using the ASIS. The sign domain is a composite of 9 items of the 17 items on the overall scale. Each of the items is assessed on a 5-point scale: 0 (best) to 4 (worst). The sign domain score is calculated as the average of the 9 items for a total possible score of 0 to 4. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening. (NCT01974141)
Timeframe: Baseline, Week 12

,
InterventionScores on a Scale (Mean)
BaselineChange from Baseline at Week 12
Dapsone Gel4.2-0.73
Dapsone Gel Vehicle4.2-0.69

Change From Baseline in Total Lesion Counts

The Investigator evaluated the patient's inflammatory (papule, pustule and nodule/cyst) and non-inflammatory (blackhead and whitehead) lesions. A papule is a small, red, solid elevation less than 1.0 cm in diameter, a pustule is a small, circumscribed elevation of the skin that contains yellow-white exudate and a nodule/cyst is a circumscribed, elevated, solid lesion generally more than 0.5 cm in diameter with palpable depth. The total lesion count was the sum of the inflammatory and non-inflammatory lesion counts. A negative change from baseline indicates a reduction in lesion counts (improvement) and a positive change from baseline indicates an increase in lesion counts (worsening). (NCT01974141)
Timeframe: Baseline, Week 12

,
InterventionTotal Lesion Counts (Least Squares Mean)
BaselineChange from Baseline at Week 12
Dapsone Gel75.9-36.9
Dapsone Gel Vehicle78.1-31.7

"Percentage of Patients Reporting Very Good or Excellent on Item 10 of the 5-Point Acne Symptom Impact Scale (ASIS)"

"The patient assessed the impact of their acne vulgaris on the look of their face using item 10 on the 5-point ASIS. Item 10 scores range from 1 (Excellent) to 5 (Bad). The percentage of patients who had an ASIS score of 4 (Fair) or 5 (Bad) at baseline and who reported Very good or Excellent at Week 12 are reported." (NCT01974323)
Timeframe: Week 12

InterventionPercentage of Patients (Number)
Dapsone Gel24.2
Dapsone Gel Vehicle22.0

Percentage Change From Baseline in Total Lesion Counts

The Investigator evaluated the patient's Inflammatory (papule, pustule and nodule/cyst) and Non-inflammatory (blackhead and whitehead) lesions. A papule is a small, red, solid elevation less than 1.0 cm in diameter, a pustule is a small, circumscribed elevation of the skin that contains yellow-white exudate and a nodule/cyst is a circumscribed, elevated, solid lesion generally more than 0.5 cm in diameter with palpable depth. The total lesion count was the sum of the inflammatory and non-inflammatory lesion counts. A negative percent change from baseline indicates a reduction in lesion counts (improvement) and a positive percent change from baseline indicates an increase in lesion counts (worsening). (NCT01974323)
Timeframe: Baseline, Week 12

InterventionPercent Change in Lesion Count (Least Squares Mean)
Dapsone Gel-48.9
Dapsone Gel Vehicle-43.2

Percentage of Patients Reporting at Least a 1-Grade Improvement From Baseline in Facial Oiliness on a the 5-Point ASIS Scale

The patient assessed their facial oiliness using item 1 on the 5-point ASIS. Item 1 scores ranged from 0 (Not at all oily) to 4 (Very oily). The percentage of patients who reported at least a 1-grade improvement from baseline in their facial oiliness are reported. (NCT01974323)
Timeframe: Baseline, Week 12

InterventionPercentage of Patients (Number)
Dapsone Gel48.5
Dapsone Gel Vehicle49.3

Percentage of Patients Reporting at Least a 1-Grade Improvement From Baseline in Facial Redness on a the 5-Point ASIS Scale

The patient assessed their facial redness using item 8 on the 5-point ASIS. Item 8 scores ranged from 0 (Not at all red) to 4 (Very red). The percentage of patients who reported at least a 1-grade improvement from baseline in their facial redness are reported. (NCT01974323)
Timeframe: Baseline, Week 12

InterventionPercentage of Patients (Number)
Dapsone Gel53.8
Dapsone Gel Vehicle52.9

Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS)

The Investigator evaluated the patient's acne severity using the 5-point GAAS scale with 0 being none and 4 being severe. The complete scale is as follow: Grade 0 (none) = No evidence of facila acne vulgaris; Grade 1 (minimal) = Few noninflammatory lesions (comedones) are present, a few inflammatory lesions (papules/pustules) may be present, no nodulo-cyctic lesions are allowed; Grade 2 (mild) = Several to many noninflammatory lesions (comedones) are present, a few inflammatory lesions (papules/pustules) are present, no nodulo-cystic lesions are allowed; Grade 3 (moderate) = Many noninflammatory (comedones) and inflammatory lesions (papules/pustules) are present, no nodulo-cystic lesions are allowed; Grade 4 (severe) = Significant degree of inflammatory disease, papules/pustules are a predominant feature, a few nodulo-cystic lesions may be present, comedones may be present. (NCT01974323)
Timeframe: Week 12

InterventionPercentage of Patients (Number)
Dapsone Gel29.8
Dapsone Gel Vehicle20.9

Change From Baseline in Inflammatory Facial Lesion Counts

The Investigator evaluated the patient's inflammatory lesions (papule, pustule and nodule/cyst). A negative change from baseline indicates a reduction in lesion counts (improvement) and a positive change from baseline indicates an increase in lesion counts (worsening). (NCT01974323)
Timeframe: Baseline, Week 12

,
InterventionNumber of Inflammatory Lesions (Mean)
BaselineChange from Baseline at Week 12
Dapsone Gel29.6-15.6
Dapsone Gel Vehicle30.0-14.0

Change From Baseline in Noninflammatory Facial Lesion Counts

The Investigator evaluated the patient's noninflammatory lesions (papule, pustule and nodule/cyst). A negative change from baseline indicates a reduction in lesion counts (improvement) and a positive change from baseline indicates an increase in lesion counts (worsening). (NCT01974323)
Timeframe: Baseline, Week 12

,
InterventionNumber of Noninflammatory Lesions (Mean)
BaselineChange from Baseline at Week 12
Dapsone Gel46.7-20.8
Dapsone Gel Vehicle46.7-18.7

Change From Baseline in the 9-Item ASIS Sign Domain Score

The patient assessed signs of acne vulgaris using the ASIS. The sign domain is a composite of 9 items of the 17 items on the overall scale. Each of the items is assessed on a 5-point scale: 0 (best) to 4 (worst). The sign domain score is calculated as the average of the 9 items for a total possible score of 0 to 4. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening. (NCT01974323)
Timeframe: Baseline, Week 12

,
InterventionScores on a Scale (Mean)
BaselineChange from Baseline at Week 12
Dapsone Gel2.04-0.74
Dapsone Gel Vehicle2.07-0.68

Change From Baseline in Total Lesion Counts

The Investigator evaluated the patient's inflammatory (papule, pustule and nodule/cyst) and non-inflammatory (blackhead and whitehead) lesions. A papule is a small, red, solid elevation less than 1.0 cm in diameter, a pustule is a small, circumscribed elevation of the skin that contains yellow-white exudate and a nodule/cyst is a circumscribed, elevated, solid lesion generally more than 0.5 cm in diameter with palpable depth. The total lesion count was the sum of the inflammatory and non-inflammatory lesion counts. A negative change from baseline indicates a reduction in lesion counts (improvement) and a positive change from baseline indicates an increase in lesion counts (worsening). (NCT01974323)
Timeframe: Baseline, Week 12

,
InterventionTotal Lesion Counts (Least Squares Mean)
BaselineChange from Baseline at Week 12
Dapsone Gel76.4-36.2
Dapsone Gel Vehicle76.9-32.3

Maximum Plasma Level (Cmax) of Dapsone

Cmax is the maximum plasma level following multiple doses of dapsone. Plasma is the liquid component of the blood in which the blood cells are suspended. (NCT01773122)
Timeframe: Day 28

InterventionNanograms/Milliliter (ng/mL) (Mean)
Dapsone Formulation A11.7
Dapsone Formulation B14.1
Dapsone Formulation C13.0
Dapsone 5% Gel17.6

Maximum Plasma Level (Cmax) of Dapsone Metabolites

Cmax is the maximum plasma level following multiple doses of dapsone. Plasma is the liquid component of the blood in which the blood cells are suspended. The dapsone metabolites are N-acetyl dapsone and dapsone hydroxylamine. (NCT01773122)
Timeframe: Day 28

,,,
InterventionNanograms/Milliliter (ng/mL) (Mean)
N-Acetyl DapsoneDapsone Hydroxylamine
Dapsone 5% Gel11.71.47
Dapsone Formulation A5.440.908
Dapsone Formulation B6.001.11
Dapsone Formulation C6.471.19

Reviews

21 reviews available for dapsone and Acne

ArticleYear
Dapsone for the treatment of acne vulgaris: do the risks outweigh the benefits?
    Cutaneous and ocular toxicology, 2022, Volume: 41, Issue:1

    Topics: Acne Vulgaris; Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Dapsone; Humans; Sul

2022
Topical dapsone in the treatment of acne: a systematic review.
    International journal of dermatology, 2022, Volume: 61, Issue:11

    Topics: Acne Vulgaris; Benzoyl Peroxide; Clindamycin; Dapsone; Doxycycline; Humans; Isotretinoin; Retinoids

2022
Efficacy and safety of dapsone gel for acne: a systematic review and meta-analysis.
    Annals of palliative medicine, 2022, Volume: 11, Issue:2

    Topics: Acne Vulgaris; Anti-Bacterial Agents; Dapsone; Eczema; Female; Humans; Treatment Outcome; United Sta

2022
Update on the use of dapsone in dermatology.
    International journal of dermatology, 2020, Volume: 59, Issue:7

    Topics: Acne Vulgaris; Anti-Infective Agents; Anti-Inflammatory Agents; Dapsone; Dermatitis Herpetiformis; D

2020
Dapsone for acne: Still in use after half a century!
    Journal of cosmetic dermatology, 2021, Volume: 20, Issue:7

    Topics: Acne Vulgaris; Dapsone; Evidence-Based Medicine; Humans; Isotretinoin

2021
Management of comedonal acne vulgaris with fixed-combination topical therapy.
    Journal of cosmetic dermatology, 2018, Volume: 17, Issue:2

    Topics: Acne Vulgaris; Adapalene, Benzoyl Peroxide Drug Combination; Administration, Cutaneous; Benzoyl Pero

2018
An Overview of Acne Therapy, Part 1: Topical therapy, Oral Antibiotics, Laser and Light Therapy, and Dietary Interventions.
    Dermatologic clinics, 2019, Volume: 37, Issue:2

    Topics: Acne Vulgaris; Administration, Cutaneous; Administration, Oral; Anti-Bacterial Agents; Combined Moda

2019
Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2015, Volume: 29, Issue:11

    Topics: Acne Vulgaris; Anti-Infective Agents; Cyclosporine; Dapsone; Dermatologic Agents; Drug Therapy, Comb

2015
What's new in acne and rosacea?
    Seminars in cutaneous medicine and surgery, 2016, Volume: 35, Issue:2

    Topics: Acne Vulgaris; Brimonidine Tartrate; Dapsone; Dermatologic Agents; Dermatology; Gels; Humans; Isotre

2016
Dapsone 7.5% Gel: A Review in Acne Vulgaris.
    American journal of clinical dermatology, 2017, Volume: 18, Issue:1

    Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Anti-Infective Agents; Child; Dapsone;

2017
Pyoderma gangrenosum following isotretinoin therapy for acne nodulocystic.
    International journal of dermatology, 2008, Volume: 47, Issue:9

    Topics: Acne Vulgaris; Dapsone; Follow-Up Studies; Humans; Isotretinoin; Male; Prednisone; Pyoderma Gangreno

2008
Aczone, a topical gel formulation of the antibacterial, anti-inflammatory dapsone for the treatment of acne.
    Current opinion in investigational drugs (London, England : 2000), 2009, Volume: 10, Issue:5

    Topics: Acne Vulgaris; Administration, Topical; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, No

2009
Dapsone 5% gel: a review of its efficacy and safety in the treatment of acne vulgaris.
    American journal of clinical dermatology, 2009, Volume: 10, Issue:4

    Topics: Acne Vulgaris; Administration, Cutaneous; Anti-Infective Agents; Clinical Trials as Topic; Dapsone;

2009
An evaluation of dapsone gel 5% in the treatment of acne vulgaris.
    Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:9

    Topics: Acne Vulgaris; Administration, Topical; Animals; Dapsone; Drug Evaluation; Gels; Humans; Treatment O

2009
Harnessing the anti-inflammatory effects of topical dapsone for management of acne.
    Journal of drugs in dermatology : JDD, 2010, Volume: 9, Issue:6

    Topics: Acne Vulgaris; Administration, Topical; Anti-Infective Agents; Anti-Inflammatory Agents; Dapsone; Dr

2010
Diethylene glycol monoethyl ether: an emerging solvent in topical dermatology products.
    Journal of cosmetic dermatology, 2011, Volume: 10, Issue:4

    Topics: Acne Vulgaris; Anti-Infective Agents; Cosmetics; Dapsone; Ethylene Glycols; Humans; Skin; Skin Absor

2011
Less common methods to treat acne.
    Dermatology (Basel, Switzerland), 2003, Volume: 206, Issue:1

    Topics: Acne Vulgaris; Anti-Infective Agents; Calcium Compounds; Cryotherapy; Dapsone; Electrocoagulation; G

2003
[Adjunctive treatments for acne therapy].
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2005, Volume: 3, Issue:2

    Topics: Acne Vulgaris; Anti-Infective Agents; Combined Modality Therapy; Dapsone; Debridement; Dermatologic

2005
Newer topical therapies for the treatment of acne vulgaris.
    Cutis, 2007, Volume: 80, Issue:5

    Topics: Acne Vulgaris; Administration, Topical; Anti-Infective Agents; Clindamycin; Dapsone; Drug Combinatio

2007
[Acne: pathogenesis and therapy].
    Nederlands tijdschrift voor geneeskunde, 1983, Jul-16, Volume: 127, Issue:29

    Topics: Acne Vulgaris; Androgen Antagonists; Androgens; Anti-Bacterial Agents; Bacterial Infections; Benzoyl

1983
[Positive side-effects of antibiotic and antimicrobial drugs in therapy (author's transl)].
    Infection, 1979, Volume: 7 Suppl 6

    Topics: Acne Vulgaris; Acrodermatitis; Adolescent; Anti-Bacterial Agents; Child; Dapsone; Dermatitis Herpeti

1979

Trials

20 trials available for dapsone and Acne

ArticleYear
Treatment Response With Once-Daily Topical Dapsone Gel, 7.5% for Acne Vulgaris: Subgroup Analysis of Pooled Data from Two Randomized, Double-Blind Stu.
    Journal of drugs in dermatology : JDD, 2017, Jun-01, Volume: 16, Issue:6

    Topics: Acne Vulgaris; Administration, Topical; Adolescent; Age Factors; Child; Dapsone; Dermatologic Agents

2017
Efficacy, Safety, and Tolerability of Topical Dapsone Gel, 7.5% for Treatment of Acne Vulgaris by Fitzpatrick Skin Phototype.
    Journal of drugs in dermatology : JDD, 2018, Feb-01, Volume: 17, Issue:2

    Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Anti-Infective Agents; Child; Dapsone; Do

2018
Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females
    Journal of drugs in dermatology : JDD, 2018, 11-01, Volume: 17, Issue:11

    Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Anti-Infective Agents; Dapsone; Double-

2018
Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females
    Journal of drugs in dermatology : JDD, 2018, 11-01, Volume: 17, Issue:11

    Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Anti-Infective Agents; Dapsone; Double-

2018
Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females
    Journal of drugs in dermatology : JDD, 2018, 11-01, Volume: 17, Issue:11

    Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Anti-Infective Agents; Dapsone; Double-

2018
Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females
    Journal of drugs in dermatology : JDD, 2018, 11-01, Volume: 17, Issue:11

    Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Anti-Infective Agents; Dapsone; Double-

2018
Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females
    Journal of drugs in dermatology : JDD, 2018, 11-01, Volume: 17, Issue:11

    Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Anti-Infective Agents; Dapsone; Double-

2018
Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females
    Journal of drugs in dermatology : JDD, 2018, 11-01, Volume: 17, Issue:11

    Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Anti-Infective Agents; Dapsone; Double-

2018
Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females
    Journal of drugs in dermatology : JDD, 2018, 11-01, Volume: 17, Issue:11

    Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Anti-Infective Agents; Dapsone; Double-

2018
Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females
    Journal of drugs in dermatology : JDD, 2018, 11-01, Volume: 17, Issue:11

    Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Anti-Infective Agents; Dapsone; Double-

2018
Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females
    Journal of drugs in dermatology : JDD, 2018, 11-01, Volume: 17, Issue:11

    Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Anti-Infective Agents; Dapsone; Double-

2018
Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females
    Journal of drugs in dermatology : JDD, 2018, 11-01, Volume: 17, Issue:11

    Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Anti-Infective Agents; Dapsone; Double-

2018
Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females
    Journal of drugs in dermatology : JDD, 2018, 11-01, Volume: 17, Issue:11

    Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Anti-Infective Agents; Dapsone; Double-

2018
Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females
    Journal of drugs in dermatology : JDD, 2018, 11-01, Volume: 17, Issue:11

    Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Anti-Infective Agents; Dapsone; Double-

2018
Usefulness of dapsone for the treatment of Asian severe acne.
    The Journal of dermatology, 2013, Volume: 40, Issue:6

    Topics: Acne Vulgaris; Adult; Anti-Infective Agents; Asian People; Dapsone; Female; Humans; Male; Middle Age

2013
Tolerability and irritation potential of four topical acne regimens in healthy subjects.
    Journal of drugs in dermatology : JDD, 2013, Jun-01, Volume: 12, Issue:6

    Topics: Acne Vulgaris; Adapalene; Administration, Cutaneous; Benzoyl Peroxide; Clindamycin; Dapsone; Dermato

2013
Use of Dapsone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Dapsone 5% Gel Combination Treatment.
    Journal of drugs in dermatology : JDD, 2016, Volume: 15, Issue:2

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Adolescent; Adult; Anti-Bacterial Agen

2016
The Efficacy and Safety of Topical Dapsone Gel, 5% for the Treatment of Acne Vulgaris in Adult Females With Skin of Color.
    Journal of drugs in dermatology : JDD, 2016, Volume: 15, Issue:2

    Topics: Acne Vulgaris; Administration, Topical; Adult; Anti-Infective Agents; Black People; Dapsone; Drug Co

2016
Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled Trials.
    Journal of drugs in dermatology : JDD, 2016, May-01, Volume: 15, Issue:5

    Topics: Acne Vulgaris; Adolescent; Adult; Anti-Infective Agents; Child; Dapsone; Double-Blind Method; Drug A

2016
Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: Second of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-Controlled Trials.
    Journal of drugs in dermatology : JDD, 2016, Aug-01, Volume: 15, Issue:8

    Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Child; Dapsone; Double-Blind Method; Drug

2016
Safety and Pharmacokinetics of Once-Daily Dapsone Gel, 7.5% in Patients With Moderate Acne Vulgaris.
    Journal of drugs in dermatology : JDD, 2016, Oct-01, Volume: 15, Issue:10

    Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Anti-Infective Agents; Dapsone; Double-Bl

2016
Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris.
    Archives of dermatology, 2008, Volume: 144, Issue:12

    Topics: Acne Vulgaris; Adolescent; Adult; Anemia, Hemolytic; Child; Cross-Over Studies; Dapsone; Dermatologi

2008
Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12-week, randomized, double-blind study.
    Journal of drugs in dermatology : JDD, 2010, Volume: 9, Issue:1

    Topics: Acne Vulgaris; Adapalene; Adolescent; Adult; Benzoyl Peroxide; Child; Dapsone; Dermatologic Agents;

2010
Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris.
    Journal of drugs in dermatology : JDD, 2011, Volume: 10, Issue:7

    Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents; Child; Dapsone;

2011
The efficacy and tolerability of dapsone 5% gel in female vs male patients with facial acne vulgaris: gender as a clinically relevant outcome variable.
    Journal of drugs in dermatology : JDD, 2012, Volume: 11, Issue:12

    Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Anti-Infective Agents; Child; Dapsone; Do

2012
Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris.
    Journal of the American Academy of Dermatology, 2007, Volume: 56, Issue:3

    Topics: Acne Vulgaris; Adolescent; Adult; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Ch

2007
Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris.
    Clinical pharmacokinetics, 2007, Volume: 46, Issue:8

    Topics: Acne Vulgaris; Adolescent; Adult; Anti-Infective Agents; Area Under Curve; Child; Cross-Over Studies

2007
Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment.
    Journal of drugs in dermatology : JDD, 2007, Volume: 6, Issue:10

    Topics: Acne Vulgaris; Adolescent; Adult; Aged; Anti-Infective Agents; Child; Dapsone; Female; Gels; Humans;

2007
Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents.
    Cutis, 2008, Volume: 81, Issue:2

    Topics: Acne Vulgaris; Administration, Topical; Adolescent; Canada; Dapsone; Double-Blind Method; Female; Fo

2008

Other Studies

29 other studies available for dapsone and Acne

ArticleYear
D-optimal mixture design for optimization of topical dapsone niosomes: in vitro characterization and in vivo activity against
    Drug delivery, 2022, Volume: 29, Issue:1

    Topics: Acne Vulgaris; Animals; Dapsone; Liposomes; Mice; Particle Size; Skin; Skin Absorption

2022
Dapsone-Loaded Mixed Micellar Gel for Treatment OF Acne Vulgaris.
    AAPS PharmSciTech, 2023, Apr-26, Volume: 24, Issue:5

    Topics: Acne Vulgaris; Animals; Dapsone; Drug Carriers; Gels; Micelles; Particle Size; Poloxamer; Rats

2023
Isotretinoin-induced Acne Fulminans without Systemic Symptoms Treated Successfully with Oral Dapsone.
    Acta dermato-venereologica, 2020, Jan-23, Volume: 100, Issue:1

    Topics: Acne Vulgaris; Administration, Oral; Adolescent; Dapsone; Dermatologic Agents; Humans; Isotretinoin;

2020
Severe methemoglobinemia due to topical dapsone misuse in a teenage girl.
    Pediatric dermatology, 2020, Volume: 37, Issue:2

    Topics: Acne Vulgaris; Administration, Topical; Adolescent; Anti-Infective Agents; Dapsone; Drug Misuse; Fem

2020
Successful treatment of acne fulminans with the combination of prednisolone and diaminodiphenylsulfone.
    The Journal of dermatology, 2021, Volume: 48, Issue:2

    Topics: Acne Vulgaris; Dapsone; Humans; Isotretinoin; Prednisolone

2021
Clinical Experience With Once-Daily Dapsone Gel, 7.5% Monotherapy in Patients With Acne Vulgaris.
    Journal of drugs in dermatology : JDD, 2018, Jun-01, Volume: 17, Issue:6

    Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Anti-Infective Agents; Dapsone; Drug Admi

2018
Successful treatment of PAPA syndrome with minocycline, dapsone, deflazacort and methotrexate: a cost-effective therapy with a 2-year follow-up.
    Clinical and experimental dermatology, 2019, Volume: 44, Issue:5

    Topics: Acne Vulgaris; Anti-Inflammatory Agents; Arthritis, Infectious; Cost-Benefit Analysis; Dapsone; Derm

2019
Mechanistic insight into the activity of a sulfone compound dapsone on Propionibacterium (Newly Reclassified as Cutibacterium) Acnes-mediated cytokine production.
    Experimental dermatology, 2019, Volume: 28, Issue:2

    Topics: Acne Vulgaris; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Cell Prolifer

2019
Bilosomes as a novel carrier for the cutaneous delivery for dapsone as a potential treatment of acne: preparation, characterization and
    Journal of liposome research, 2020, Volume: 30, Issue:1

    Topics: Acne Vulgaris; Administration, Cutaneous; Animals; Anti-Infective Agents; Bile Acids and Salts; Biol

2020
Acne vulgaris in the context of complex medical co-morbities: the management of severe acne vulgaris in a female with retinitis pigmentosa - utilizing pulse dye laser in conjunction with medical therapy.
    Dermatology online journal, 2014, Mar-17, Volume: 20, Issue:3

    Topics: Acne Vulgaris; Administration, Cutaneous; Adult; Androstenes; Anti-Infective Agents, Local; Combined

2014
Resolution of nodulocystic acne with oral dapsone.
    Dermatologic therapy, 2017, Volume: 30, Issue:1

    Topics: Acne Vulgaris; Administration, Oral; Adolescent; Dapsone; Dermatologic Agents; Humans; Male; Remissi

2017
Interaction of topical sulfacetamide and topical dapsone with benzoyl peroxide.
    Archives of dermatology, 2009, Volume: 145, Issue:9

    Topics: Acne Vulgaris; Administration, Topical; Anti-Infective Agents, Local; Benzoyl Peroxide; Dapsone; Der

2009
Is topical dapsone safe in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients?
    Journal of drugs in dermatology : JDD, 2010, Volume: 9, Issue:5

    Topics: Acne Vulgaris; Administration, Cutaneous; Clinical Trials as Topic; Dapsone; Dermatologic Agents; Dr

2010
A case of acne fulminans in a patient with ulcerative colitis successfully treated with prednisolone and diaminodiphenylsulfone: a literature review of acne fulminans, rosacea fulminans and neutrophilic dermatoses occurring in the setting of inflammatory
    Dermatology (Basel, Switzerland), 2011, Volume: 222, Issue:3

    Topics: Acne Vulgaris; Anti-Inflammatory Agents; Biopsy; Cefozopran; Cephalosporins; Colitis, Ulcerative; Da

2011
Cystic acne successfully treated with diaminodiphenylsulfone.
    The Journal of dermatology, 2011, Volume: 38, Issue:5

    Topics: Acne Vulgaris; Dapsone; Dermatologic Agents; Female; Humans; Severity of Illness Index; Treatment Ou

2011
Dapsone 5% gel: a new option in topical therapy for acne.
    Skin therapy letter, 2012, Volume: 17, Issue:8

    Topics: Acne Vulgaris; Administration, Topical; Anti-Infective Agents; Anti-Inflammatory Agents; Dapsone; Ge

2012
The treatment of acne vulgaris with dapsone.
    The British journal of dermatology, 1961, Volume: 73

    Topics: Acne Vulgaris; Dapsone; Humans; Sulfones

1961
Dapsone--other indications.
    International journal of dermatology, 1982, Volume: 21, Issue:9

    Topics: Acne Vulgaris; Adolescent; Animals; Dapsone; Dermatitis Herpetiformis; Humans; Male; Pemphigoid, Bul

1982
[Experience with Disulone in the treatment of severe nodular acne].
    LARC medical, 1981, Volume: 1, Issue:3

    Topics: Acne Vulgaris; Adult; Dapsone; Female; Humans; Male; Retrospective Studies

1981
Successful treatment of acute dapsone intoxication using charcoal hemoperfusion.
    Australian and New Zealand journal of medicine, 1983, Volume: 13, Issue:5

    Topics: Acne Vulgaris; Adult; Charcoal; Dapsone; Female; Hemolysis; Hemoperfusion; Humans; Hypoxia; Methemog

1983
How I treat acne.
    Medical times, 1980, Volume: 108, Issue:3

    Topics: Acne Vulgaris; Adolescent; Adrenal Cortex Hormones; Anti-Bacterial Agents; Benzoyl Peroxide; Dapsone

1980
Dapsone hypersensitivity. The sulfone syndrome revisited.
    Archives of dermatology, 1981, Volume: 117, Issue:1

    Topics: Acne Vulgaris; Adolescent; Anemia, Hemolytic; Chemical and Drug Induced Liver Injury; Dapsone; Drug

1981
Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone.
    Clinical and experimental dermatology, 1997, Volume: 22, Issue:1

    Topics: Acne Vulgaris; Adolescent; Anti-Infective Agents; Dapsone; Erythema Nodosum; Humans; Isotretinoin; K

1997
The sulfone syndrome complicated by pancreatitis and pleural effusion in an adolescent receiving dapsone for treatment of acne vulgaris.
    Journal of pediatric gastroenterology and nutrition, 1998, Volume: 26, Issue:1

    Topics: Acne Vulgaris; Adolescent; Dapsone; Humans; Male; Mexico; Pancreatitis; Pleural Effusion; Sulfones;

1998
[Acne inversa: a dapsone-sensitive dermatosis].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2001, Volume: 52, Issue:10 Pt 2

    Topics: Acne Vulgaris; Adult; Aged; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Chronic

2001
Dapsone-induced peripheral neuropathy.
    Archives of neurology, 1977, Volume: 34, Issue:10

    Topics: Acne Vulgaris; Adolescent; Dapsone; Humans; Male; Peripheral Nervous System Diseases

1977
Acne fulminans with dapsone induced haemolysis: a case report.
    The Medical journal of Malaysia, 1987, Volume: 42, Issue:2

    Topics: Acne Vulgaris; Adult; Anemia, Hemolytic; Dapsone; Female; Humans

1987
[DDS in the treatment of necrotic acne].
    Vestnik dermatologii i venerologii, 1988, Issue:6

    Topics: Acne Vulgaris; Adult; Chronic Disease; Dapsone; Drug Evaluation; Female; Humans; Male; Middle Aged;

1988
A comparison of dapsone with 13-cis retinoic acid in the treatment of nodular cystic acne.
    Clinical and experimental dermatology, 1988, Volume: 13, Issue:2

    Topics: Acne Vulgaris; Adolescent; Adult; Dapsone; Humans; Isotretinoin; Male

1988